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Perceptions of the clinical management of delusional 
infestation (DI) were compared with clinical outco-
mes in this 10-year case series from a single centre in 
Dundee, UK. An online questionnaire (survey-monkey, 
a TM brand of online survey available for free for ba-
sic use) was sent to Scottish Dermatologists to gauge 
their opinions and confidence in the management of 
DI. Also, a retrospective review of medical case notes 
of patients seen by dermatologists in one institution 
was undertaken and clinical outcomes were repor-
ted by patients’ general practitioners (GP). The sur-
vey showed that 61% of responding dermatologists 
encountered 1–5 cases of DI per year. Twenty-four 
percent respondees were ‘confident’ in managing pa-
tients with DI, 54% were ‘somewhat confident’. Forty-
seven patients (62% female, 70% single) were seen 
over the 10 years; 43% brought a self-collected spe-
cimen to clinic, 68% of patients had a psychiatric co-
morbidity, 23% of patients had primary DI and 11/47 
(23%) were seen by a psychiatrist. Clinical outcomes 
as rated by patients’ GPs were reasonable or good in 
2/3 patients. A poor outcome was seen in 12 patients 
and associated with chronic pain in 50% (p < 0.01) and 
psychiatric comorbidity in 100% (p < 0.01). We con-
clude that good outcomes can be achieved in some pa-
tients with DI without psychiatric input and without 
psychoactive treatment.
Key words: delusional; infestation; parasitosis; psychoderma-
tology.
Accepted Dec 20, 2017; Epub ahead of print Dec 21, 2017
Acta Derm Venerol 2018; 98: xx–xx.
Corr: Yee Ling Wong, Department of Dermatology, Ninewells Hospital, 
NHS Tayside, DD2 1UU Dundee, United Kingdom. E-mail: yeelingwong@
nhs.net 
Delusional infestation (DI) is a condition characte-rised by false, firmly held beliefs of infestation, 
involving either living or inanimate pathogens, despite 
objective evidence suggesting otherwise (1). The prefer-
red term DI is often used interchangeably with delusions 
of parasitosis (which is too restrictive and suggests a 
specific aetiology), Ekbom’s syndrome, and Morgellons 
disease (2). Primary DI develops without any underlying 
physical or psychiatric cause whereas secondary DI oc-
curs in the context of an underlying disorder including 
substance misuse, psychiatric illness, medication side 
effects and physical or structural brain abnormalities (3). 
Presenting clinical features include stinging, biting and 
crawling sensations, which may be associated with psy-
chological distress and anxiety (4). Affected individuals 
often employ various methods of eradication and may 
inflict considerable damage to the skin in their efforts to 
remove the perceived infesting agent. (4). A proportion 
of patients (up to 75%) bring samples of the presumed 
pathogen to the clinic in an attempt to convince their 
doctor of the infestation. This is known as the ‘matchbox 
sign or ‘specimen sign’ (5). The ‘matchbox sign’ is a 
somewhat archaic term still used by many practitioners. 
Recent expert commentary has suggested that the “spe-
cimen sign” is a more suitable term as it is important 
whether the patient brings the specimen for examination 
regardless of which carrier the specimen is in (6). DI is 
a rare disorder, with an estimated incidence of 1.9 in 
100,000 person years although it may be increasing (3). 
The prevalence is unknown due to the lack of population-
based epidemiological research (5). Many patients are 
often reluctant to see a psychiatrist and lack insight. The 
challenges presented to the dermatologist and suggestions 
for clinical management are described elsewhere (3).
In this 10-year retrospective study we aim to compare 
and contrast the demographic detail and co-morbidities 
with previously reported case series of DI, highlighting 
the clinical outcomes in relation to patient factors and 
different management strategies.
METHODS
There were two parts of this study:
1) In this first part of the study, the aim was to reveal how many 
dermatologists were happy to treat DI and how many considered 
the outcome of DI to be poor.
An online questionnaire was sent to all members of the Scottish 
Dermatology Society (SDS) to gauge their opinions and con-
fidence in the management of DI. A total of 55 dermatologists 
responded in May 2017 (24% response rate). The questions 
asked and the answers are summarised in Table SI1.
2) The second part of the study was designed to assess outcomes 
of the disorder.
Following Caldicott Guardian approval to ensure minimal 
use of patient identifiable data and transfer of information, 
a retrospective review of medical case notes of patients seen 
by dermatologists in Ninewells Hospital & Medical School, 
Scotland over the 10-year period (2007–2016) was undertaken. 
Fifty-eight patient records were retrieved from an electronic 
clinical database using the search terms ‘delusional”, “infesta-
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tion’, ‘morgellons’, ‘ekbom’ and ‘delusions of parasitosis’. 
Inclusion criteria included patients who met the criteria for DI 
as outlined in Freudenmann and Lepping’s 2009 review. Other 
psychodermatological conditions derived from the search terms 
including acne excoriee and body dysmorphic disorder were 
excluded, leaving 47 patients in this case series. Data obtained 
included demographic information, symptom duration, referral 
source, presence of specimen sign, specimen types (examined 
and analysed microscopically by several specialties including 
pathology, microbiology, parasitology and plant science) and 
co–morbid medical and psychiatric conditions. Finally, to assess 
outcomes, written questionnaires with stamped return envelopes 
were sent to the patients’ general practitioner (GP) to gather 
follow-up data on emotional state, psychotropic medication 
and whether there had been any relapse of DI symptomatology. 
Statistics
A chi-square method was utilised to confirm the statistical signi-
ficance of differences between groups. p < 0.01 was considered 
statistically significant.
RESULTS
Questionnaire study
Of the 229 online questionnaires sent, 55 responses were 
obtained (see Table SI1). During their career to date, 
98% dermatologists who responded to the survey had 
encountered patients with DI. 61% had encountered 1–5 
cases of DI per year. 24% respondees were ‘confident’ 
in managing patients with DI, 54% were ‘somewhat 
confident’ and 22% were ‘not confident at all’. Out 
of 55 dermatologists, 49% felt confident to prescribe 
psychotropic medications to patients with DI without 
liaising with psychiatry. Some of the major challenges 
volunteered included engagement in treatment, strains 
in the doctor–patient relationship, time pressures in a 
general dermatology clinic, and reluctance to accept 
diagnosis. Among this group, 38/55 (69%) dermato-
logists had more than 10 years of experience. Of the 
38 responses, 19 (50%) thought outcome was poor, 
followed by 12 (32%) who were unsure of the likely 
clinical course, and 7 (18%) who considered outcome 
to be potentially good.
Case series
Of the 47 patients, 62% were women (female-to-male 
ratio of 1.6 to 1), with a mean age of 55 years. The mean 
duration of symptoms prior to first presentation at a der-
matology clinic was 12 months. GPs referred the majority 
of these patients. Only 3/47 patients were referred by 
another specialty (infectious disease, sexual health clinic 
and psychiatry) (Table SII1). Following referral, 27 (57%) 
were managed by a dermatologist with special interest in 
psychodermatology, 9 (19%) by various general derma-
tologists, 6 patients (13%) were referred to psychiatry, 
4 (9%) were seen in a joint psychodermatology clinic 
(established in 2014) and 1 patient (2%) was admitted 
for in-patient psychiatric treatment.
With regard to comorbidities (Table SIII1), 81% of the 
patients were found to have no dermatological history. 
68% had psychiatric comorbidities that included depres-
sion, anxiety, obsessive-compulsive disorder, psychosis, 
bipolar affective disorder, hypomania and encopresis, 
32% had no psychiatric comorbidity; 23% had chronic 
pain. Medications used included anti-parasitic drugs 
(36%) and topical steroids (Table SIV1). In terms of 
substance use, 5 (11%) were taking stimulants (amp-
hetamine/cocaine); 5 (11%) used opiates (morphine/
codeine); 7 (15%) were heavy smokers; 3 (6%) were al-
cohol dependent; and 2 (4%) concomitantly used alcohol 
and tobacco. Twenty-five (53%) denied any history of 
substance use (including alcohol and tobacco). 
Dermatological findings, managements and follow-up
On physical examination excoriations dominated (n = 21; 
44%); followed by dermatitis (n = 10; 21%) and pruritus 
(n = 10; 21%), ulceration (n = 6; 13%), lichen simplex 
(n = 5; 11%) and papules (n = 4; 9%). Normal skin was 
present in 8 patients (17%) patients. (Note that the per-
centage adds up over 100% due to multiple, coexisting 
dermatological findings).
At the time of the study, 10 patients were deceased and 
therefore excluded from outcome measures. The cause 
of death for these 10 patients was: 3 cancer, 1 probable 
suicide, 2 old age, 1 hip fracture, 1 community-acquired 
pneumonia, 1 stroke and 1 exacerbation of chronic ob-
structive pulmonary disease. Of the 37 questionnaires 
sent to GPs enquiring about outcomes specific to their 
patient, 36 were completed and returned in June 2017 
(response rate 97%). In terms of emotional well-being, 
17 (47%) of GPs considered their patient to have ‘good’ 
well-being, 7 (19%) reported ‘average’ well-being and 
12 (33%) reported ‘poor’ well-being; 26 (72%) of the 
patients had not had a further relapse following clinic 
Table I. Detailed profile of 17 patients with ‘good’ outcome
No
Age, years/
Sex
Psychiatric co-
morbidities
Medication started in 
dermatology
Major 
life event
1 57/M 0 0 0
2 58/F Depression Risperidone 0
3 45/F Anxiety Fluoxetine 0
4 34/F Bipolar 0 0
5 67/M 0 Doxepin 0
6 45/F 0 0 1
7 43/M 0 0 0
8 84/F 0 0 1
9 64/Fa 0 Risperidone 1
10 63/F 0 Amitriptyline 1
11 62/F 0 0 1
12 27/F 0 Olanzapine
Referred to psychiatry
1
13 56/F OCD Nortriptyline 1
14 39/F Depression Haloperidol 0
15 68/F Depression Risperidone
Referred to psychiatry
1
16 80/F 0 0 1
17 64/F Hypomania Referred to psychiatry 0
aThis patient was the only one reporting chronic pain.
None of the patients reported any relapses or have any current psychopharmacy.
OCD: obsessive compulsive disorder.
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attendance. Fifteen patients (42%) continued on psycho-
tropic medication for DI and/or associated psychiatric 
disorder, including anti-depressant and anti-psychotic 
medications. We further compared the profiles of patients 
who had ’good’ (Table I) to those with ‘poor’ outcome 
(Table II) and statistically analysed the difference bet-
ween the two groups in relation to pertinent psychiatric 
features, pain and major life events (Table III). 
DISCUSSION 
In this retrospective case series, the demographic profile 
resembles other studies including a study from the Euro-
pean multicentre study (n = 148) (6), the Mayo Clinic in 
Rochester, USA (n = 147) (7), and an Australian multi-
centre study (n = 23) (2). These studies demonstrated that 
the majority of patients were women with a mean age 
of 56 years. In our study, 29/47 (62%) were female with 
a mean age of 55 years. Seventy percent of the patients 
were single (34%), divorced (15%), or widowed (21%). 
Seventy-nine percent of patients were unemployed; 21 
(45%) were unable to work due to illness and 16 (34%) 
were retired. Contrasting our results, an American study 
reported that the majority of the patients from their cohort 
were married and not socially isolated (7). However, 
our results are consistent with the demographic data of 
most other reported studies in that single, older women 
who are socially isolated are most commonly affected 
by DI (8, 9). 
The European multicentre study by Freudenmann et al. 
reported that no patients presenting with DI had a genuine 
infestation and that the specimen sign was present in 48% 
of all cases (6). Our case series revealed similar results, 
the specimen sign being present in 21 (45%) of cases.
Szepietowski et al. (10) in a survey of Polish derma-
tologists reported on the management of DI. The results 
showed that 85% of dermatologists had seen at least 
one patient with DI in their practice, compared to 98% 
in our study. The study also showed that 40.7% of the 
respondents ‘always ask’ and 28.8% ‘often ask’ for a 
psychiatric opinion. Interestingly, only 15.3% of derma-
tologists from the study would use their own pharmaco-
logical treatment such as sedatives and anxiety-relieving 
medications, prompting the authors to suggest an urgent 
need for psychodermatological training among dermato-
logists (10). This is much lower than the 49% of Scottish 
dermatologists who reported a willingness to prescribe 
a psychoactive medication in our study.
There are few reports detailing the specimen types 
and analysis in patients with DI. Nonetheless, this can 
be an important part of management and shows that 
the clinician is taking the patient’s concerns seriously. 
A study conducted by Hylwa et al. (11) was the first to 
address patient-provided specimens presenting with 
DI, although only 20 out of 80 samples were sent for 
microscopic evaluation. 
Our study provided a complete set of data on analysed 
specimens presented to our centre. Of the 21 patients 
who brought specimens, 5 (24%) were skin squames, 5 
(24%) were organic debris, 4 (19%) were actual insects, 
3 (14%) were inorganic debris, and the remaining were 
hair 1 (5%), eyebrow 1 (5%) and 2 (10%) stool samples. 
According to Lepping et al. (3), approximately half of 
all presentations in large case studies are primary delu-
sional disorder. Our case series revealed that only 11/47 
(23%) patients had primary DI ie. no neuropathology 
(stroke/ motor neurone disease/meningitis), history of 
substance use or psychiatric co-morbidities. This is very 
similar to the findings of Foster et al. (7) who identified 
psychiatric co-morbidities or substance abuse in 81% of 
patients (19% primary DI).
For the treatment of primary DI, limited evidence 
from case series previously suggested pimozide as first-
Table II. Detailed profile of 12 patients with ‘poor’ outcome
No.
Age, 
years/
Sex Relapse Psychiatric co-morbidities
Medication started in 
dermatology
Current 
psychopharmacy
Under 
psychiatry
Major life 
event
Chronic 
pain
1 31/F 0 Psychotic depression Risperidone Aripiprazole; Duloxetine 1 1 1
2 64/F 0 Depression Risperidone Olanzapine;Duloxetine 1 0 1
3 48/M 0 Schizoaffective disorder Quetiapinea (Known to psychiatry) 0 1 0 1
4 37/F 1 Depression; F29.0 0 Quetiapine 1 1 0
5 58/F 0 Depression 0 (Referred to psychiatry) Aripriprazole; Duloxetine 1 1 1
6 49/F 0 Paranoid psychosis Aripiprazole (Known to psychiatry) Aripiprazole; Mirtazapine 1 0 0
7 45/M 1 Depression 0 Escitaloprama 0 1 0
8 56/F 1 Depression; hypochondrial delusion Risperidone
Referred to psychiatry
Risperidone; Citalopram 1 0 1
9 22/F 0 Depression Aripiprazole 0 0 1 0
10 52/M 1 Depression 0 Sertraline 0 0 0
11 71/F 1 Depression Haloperidol bHaloperidol 0 1 0
12 73/F 1 Anxiety Quetiapine Quetiapine 0 1 1
aPatient is non-compliant to medications. bPatient experiences medication side-effects.
Table III. Chi-square analysis of prevalence figures for some 
relevant features depending on outcome
Pertinent features
Good
(n = 17)
n (%)
Bad
(n = 12)
n (%) Chi-square p
Depressive disorder 3 (18)   9 (75)   9.084 0.0026
Associated psychiatric Dx 7 (41) 12 (100) 10.45 0.0012
Chronic pain 1 (6)   6 (50)   7.167 0.0074
Major events 9 (75)   7 (58)   0.902 0.3424
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line treatment. However, in recent years, other second-
generation anti-psychotics with a better safety profile 
are usually preferred (3, 12). We are not aware of any 
randomised studies comparing outcomes of 2 antipsy-
chotics. Pharmacological treatment should only be given 
after establishing a good relationship with the patient, as 
suggested by Patel & Koo (12). 
We acknowledge that in individual cases it may be 
difficult to determine whether the delusional disorder 
has emerged in the context of a co-morbid psychiatric 
illness or the other way around, i.e. anxiety and depres-
sion could be triggered by difficulties coping with the 
DI symptomatology.
As training, teaching and published research on psy-
chodermatological disorders has increased over the last 
10–15 years, clinicians have become more familiar with 
treatment options. Our survey has shown that a significant 
proportion of dermatologists are now reasonably confi-
dent in managing this rare and challenging condition. (3, 
5, 12). Close liaison with psychiatry is clearly desirable in 
individual cases and a joint psychodermatological clinic 
has obvious benefits as reported previously and is now 
established at our institution (4). However, we have found 
positive outcomes in our case series with 72% patients 
having no relapses since last contact with the clinic and 
66% reporting average or good well being. Only 11/47 
(23%) of patients were seen by a psychiatrist. Eleven 
patients had a coexisting chronic pain syndrome which 
could be considered somatoform in nature and we agree 
with Reichenberg et al. (13) that such patients may have a 
broader somatoform disorder which includes overvalued 
beliefs of infestation. We also agree that patients labelled 
with DI are a heterogeneous group whose beliefs exist on 
a spectrum ranging from overvalued ideas to frank delu-
sions and may include tactile hallucinations (12). Indeed, 
we suggest it may be more appropriate for a dermatolo-
gist to use the descriptive term “medically unexplained 
formication with overvalued beliefs of infestation” rather 
than “delusional” which carries the risk of inaccuracy 
when strict diagnostic criteria are applied (14). Indeed 
distinguishing an overvalued idea from a delusion can be 
a challenging task, albeit both are clearly defined:
An overvalued idea is “an acceptable, comprehensible 
idea pursued by the patient beyond the bounds of reason” 
while a delusion can be considered “a false, unshakable 
belief, generated by internal morbid processes, which 
the patient believes with conviction to be true” (15) 
(Table SV1). 
To our knowledge, this is the first study that has addres-
sed the outcomes of all patients with DI, and identified 
red flags associated with poorer outcome. The only other 
study that considered outcome was performed in 2011 
by Wong & Bewley, but only addressed the outcomes of 
patients with DI who received pharmacotherapy (16). In 
our study, 9/12 (75%) patients who had a poor outcome 
had depressive disorder compared to 3/17 (18%) who 
had a good outcome (p = 0.0026). 12/12 (100%) patients 
with a poor outcome had an associated psychiatric di-
agnosis compared to 7/17 (41%) of the good outcome 
group (p = 0.0012). 6/12 (50%) patients who had a poor 
outcome had chronic pain compared with 1/17 (6%) who 
had a good outcome (p = 0.0074). Major life events, being 
female and single were common in both poor and good 
outcome groups and so not discriminatory regarding out-
come. Seven of 17 patients (41%) with a good outcome 
were not treated with psychopharmacy compared to 2/12 
(17%) who had poor outcome. Only 3/17 (18%) patients 
in the good outcome group were seen by psychiatry com-
pared to 7/12 (58%) in the poor outcome group.
With a critical chi-square of 121.8 in contrast to a chi 
square level of 11.4 gives a p-value of p < 0.01. We can 
conclude that there is a significant difference between 
the good and poor outcome groups. 
The rate of spontaneous remissions is debatable. Ac-
cording to Table I, 7 patients with good outcome impro-
ved without pharmacological treatment. Comparing to 
the whole data set, 7/47 (15%) of spontaneous remission 
was observed. Twenty-two of 47 patients were started 
with medications including those who died. Our data 
suggested that 9/17 (53%) patients in the good outcomes 
group were started with psychotropic medications in 
dermatology and none of them are currently on psycho-
tropic medications from the GP questionnaire. From the 
average outcomes group, 2/7 (29%) patients were started 
with psychotropic medications in dermatology and 4/7 
(57%) are currently on psychotropic medications. In the 
poor outcomes group, 7/12 (58%) were started on psy-
chotropic medications and 10/12 (83%) are currently on 
psychotropic medications. An article published in 1946 
suggested that the rate of spontaneous recovery without 
psychopharmacotherapy after only dermatological treat-
ment was observed in 10% of the cases, partial remission 
in 8% of the cases and no effect in 82% of the cases (17). 
However, with increased knowledge and publications in 
the management of DI in the 71 years since this study, 
we suggest that good outcomes may be influenced by the 
holistic ability of the psychologically-minded dermatolo-
gist in talking and listening approaches rather than only 
providing dermatological treatment. 
We accept that our study has some limitations. In 
the first part, we received a low response rate from the 
Scottish Dermatology Society. This is a limitation, as 
the other 76% of the dermatologists could have given 
answers that would dramatically change the results. Due 
to the retrospective nature of case notes review in the 
second part of the study, some findings may be limited by 
incomplete data and are therefore subjected to misinter-
pretation. Outcomes, were assessed indirectly, through a 
written questionnaire completed by general practitioners, 
and not through direct examination of patients during 
follow-up. This is subjective, and is a potential source 
of systemic error. 
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In conclusion, from our study red flags that suggest 
a poorer outcome include chronic pain and psychiatric 
co-morbidity, especially depression. The presence of 
such findings should alert dermatologists to seek further 
assessment from psychiatry, ideally, in our view, at a joint 
psychodermatology clinic. A proportion of patients have 
a good outcome without psychotropic drug treatment. 
However, our findings cannot be over-stated and gene-
ralised. Larger multicentre studies looking at treatment 
of DI may be helpful in the future, by e.g. comparing 
outcomes between single-handed dermatologists versus 
combined dermatology/psychiatry clinics. Treatment of 
any underlying cause of DI is desirable and in all cases 
a trial of an antipsychotic is usually indicated and often 
helps reduce the troublesome symptoms. 
The authors have no conflicts of interest to declare.
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Supplementary material to article by Y. L. Wong et al. ”Delusional Infestation: Perspectives from Scottish Dermatologists and a 10-year Case 
Series from a Single Centre”
Table SI. Online questionnaire completed by members of the SDS (n = 55)
Dermatologists participating in this questionnaire, n (%) 
Q1. Please state your grade 
Consultant
ST1 and above
Staff Grade
Other
37 (67)
  5 (9)
  8 (15)
  5 (9)
Q2. How many years of experience in dermatology do you have? 
> 10
5 to 10
< 5 
38 (69)
11 (20)
  6 (11)
Q3. Have you encountered patients with delusional infestation? 
Yes
No
54 (98)
  1 (2)
Q4. Is ’Yes’ for the above question, how common (per year)? 
1 to 5
< 1
34 (61)
21 (39)
Q5. How confident are you at managing these patients? 
Very confident
Confident
Somewhat confident
Not confident at all
  0 (0)
13 (24)
30 (54)
12 (22)
Q6. What would be the best option in managing these patients?
In a dermatology clinic
Referral to psychiatry
A joint psycho-dermatological clinic
  2 (4)
  4 (7)
49 (89)
Q7. What are the challenges that you may encounter? 
Patient compliance
Failure to follow-up
Not trained to manage such patients
Outwith my comfort zone
Other (please specify)
14 (25)
  6 (11)
  7 (13)
14 (25)
14 (25)
Q8. What do you think of the outcome of this condition? 
Excellent
Good
Poor
Very poor
Do not know
  0 (0)
  8 (15)
30 (55)
  5 (9)
12 (22)
Q9. Are you happy to prescribe psychopharmaceutical medications to such patients? 
Yes
No
27 (49)
28 (51)
Q10. Some patients may bring specimens with them. What would you do with them?
Send for histopathology
Send for microbiology
Do not know
Do nothing
Other (please specify)
  5 (9)
25 (45)
  2 (4)
  7 (13)
16 (29)
Table SII. Demographic information for patients with delusional 
infestation from 2007–2016 (n = 47)
Demographics
Gender, n (%)
  Male
  Female
18 (38)
29 (62)
Age at initial visit, years, mean ± SD 55 ± 17
Duration of illness prior to dermatology referral, months, median (IQR)a 12 (6–18)
Number of clinic visits, mean (range)   2 (1–19)
Marital status, n (%)
  Single
  Married
  Divorced/separated
  Widowed
  Lives with partner
16 (34)
  9 (19)
  7 (15)
10 (21)
  5 (11)
Occupation, n (%)
  Employed
  Unemployed
10 (21)
37 (79)
Referral source, n (%)
  GP
  Other specialty 
  Dermatology
Year first seen in dermatology, n (%)
  2007
  2008
  2009
  2010
  2011
  2012
  2013
  2014
  2015
  2016
37 (79)
  3 (6)
  7 (15)
  1 (2)
  3 (6)
  2 (4)
  8 (17)
  5 (11)
  6 (13)
  5 (11)
  7 (15)
  5 (11)
  5 (11)
a2 missing data.
IQR: interquartile range.
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Table SIII. Concomitant co-morbidities in patients with delusional 
infestation (n = 47)
Co-morbidities
Patients
n (%)
Dermatology history
  Acne vulgaris
  Atopic dermatitis 
  Tinea pedis
  Squamous cell carcinoma
  Melanoma
  Bowen’s disease
  No dermatology history
  2 (4)
  3 (6)
  1 (2)
  1 (2)
  1 (2)
  1 (2)
38 (81)
Medical history
  Hypothyroidism
  Acne vulgaris
  Atopic dermatitis
  Cancer (prostate, breast, skin)
  Functional neurological symptoms
  Pseudo-seizures
  Chronic disease
  Recent grief
  Previous suicide attempt
  Others
  5 (11)
  2 (4)
  3 (6)
  6 (13)
  3 (6)
  2 (4)
10 (21)
  2 (4)
  2 (4)
12 (26)
Psychiatric history
  Obsessive compulsive disorder
  Depression
  Anxiety
  Paranoid psychosis
  Bipolar
  Hypomania
  Obsessive compulsive disorder and depression
  Anxiety and depression
  Encopresis (childhood)
  None
  3 (6)
17 (36)
  4 (9)
  2 (4)
  1 (2)
  1 (2)
  1 (2)
  2 (4)
  1 (2)
15 (32)
Chronic pain
  Yes
  No
11 (23)
36 (77)
Table SIV. Medications used by patients with delusional infestation 
(n = 47)
Medication
Patients
n (%)
  Anti-fungal
  Anti-parasitic
  Antibiotics
  Topical steroids
  Emollients
  Anti-histamines
  Topical steroid & anti-fungal
  Topical steroid & anti-parasitic
  Topical steroid & antibiotics
  Emollients & anti-histamines
  Emollients & topical steroids
  Anti-fungal & antibiotics
  Anti-psychotics
  No previous treatment
  2 (4)
17 (36)
  3 (6)
  5 (11)
  1 (2)
  2 (4)
  1 (2)
  3 (6)
  2 (4)
  3 (6)
  1 (2)
  1 (2)
  2 (4)
  4 (9)
Table SV. DSM-5 diagnostic criteria for delusional disorder, somatic type Code 
297.1 (16)
• Presence of a delusion of body function /sensation with a duration > one month
• The criterion for schizophrenia has never been met (tactile or olfactory hallucinations may 
be present and are related to the delusional theme (e.g. formication is associated with DI)
• Apart from the impact of the delusion (s) or its ramifications, functioning is not markedly 
impaired, and behaviour is not obviously bizarre or odd 
• If manic or major depressive episodes have occurred, these have been brief relative to the 
duration of the delusional periods 
• The disturbance is not better explained by another mental disorder such as obsessive-
compulsive disorder, and is not attributable to the physiological effects of a substance or 
medication or another medical condition
